WO2008001849A1 - Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent - Google Patents
Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent Download PDFInfo
- Publication number
- WO2008001849A1 WO2008001849A1 PCT/JP2007/063003 JP2007063003W WO2008001849A1 WO 2008001849 A1 WO2008001849 A1 WO 2008001849A1 JP 2007063003 W JP2007063003 W JP 2007063003W WO 2008001849 A1 WO2008001849 A1 WO 2008001849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wap
- solution
- injection
- cyclodextrin
- antibiotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a depsipeptide antibiotic having excellent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), WAP-8294A, an in-use preparation for injection and
- MRSA is a drug-resistant Staphylococcus aureus in which multiple antibiotics such as methicillin are no longer effective.
- the first MRSA was reported in the UK and then spread rapidly around the world.
- Today, 50-70% of Staphylococcus aureus isolated in medical facilities is said to be MRSA, and is considered to be widespread in hospitals.
- MRSA infects health care workers and patients in medical facilities mainly by contact infection, but MRSA itself is a mutant of S. aureus and has low pathogenicity. Often become a person.
- MRSA grows in the body, causing pneumonia, enteritis, MRSA infections such as sepsis, endocarditis and meningitis develop. MRSA infection is positioned as one of the most important infectious diseases in Europe, the United States, and Japan where medical care is highly developed, and various infection prevention measures are being promoted at medical sites such as hospitals.
- WAP-8294A a depsipeptide antibiotic
- WAP-8294A is particularly effective during acute exacerbation of MRSA infection due to its strong antibacterial activity
- Patent Document 1 Patent No. 3339235
- WAP-8294 A a depsipeptide antibiotic that is expected to be a therapeutic agent for MRSA infections, which is a major problem in medical practice, has a strong antibacterial effect.
- An object of the present invention is to provide a high-concentration and stable WAP-8294A in-use prepared injection solution and injection.
- WAP-8294A is a depsipeptide antibiotic having the structural formula shown in the following formula (1).
- WAP-8294A obtained as hydrochloride
- the solution is strongly acidic.
- the stability of the aqueous solution of WAP-8294A is PH and concentrated.
- 2-hydroxypropyl-j8-cyclodextrin and j8-cyclodextrin solutions are particularly WAP-8294A.
- the present invention contains 2-hydroxypropyl- ⁇ -cyclodextrin or j8-cyclodextrin as a solubilizing agent, and has the following structural formula ( 1) Injectable preparation containing antibiotic WAP-8294A as an active ingredient
- This injectable preparation is used by mixing an infusion solution or diluent and a pH adjuster at the time of use, and the pH is preferably 2-4.
- Antibiotics in injectable formulation WAP-8294 A is preferably 2-4.
- the concentration of 2 is preferably 5 to 20 mg / ml.
- the concentration of 2-hydroxypropyl- ⁇ -cyclodextrin in this preparation is preferably 2 to 50%.
- the concentration of ⁇ -cyclodextrin is preferably 0.5 to 2.5%.
- the present invention is, as a solubilizer, 2-hydroxypropyl - beta - cyclodextrin or j8 - with cyclodextrin, wherein the formulated without adjusting the P H, the structural formula (1) Antibiotics WAP-8294A as an active ingredient
- the present invention also relates to an injection administration solution of the antibiotic WAP-8294A in which an infusion solution or diluent and a pH adjuster are mixed with the above-mentioned in-use preparation type injection preparation. With this dosing solution
- the pH adjusting agent used is preferably a solution of disodium hydrogen phosphate, monosodium dihydrogen phosphate, and sodium hydroxide.
- the infusion or dilution solution is preferably dextrose.
- the present invention provides a method for producing an administration liquid for injection of the antibiotic WAP-8294A, which comprises mixing an infusion solution or diluent and a pH adjuster into the above-mentioned preparation for use at the time of use.
- the ready-to-use injectable preparation of the present invention contains 2-hydroxypropyl- ⁇ -cyclodextrin or j8-cyclodextrin as a solubilizer or stabilizer, and is formulated without adjusting the pH.
- the WAP-8294A aqueous solution has poor gel stability.
- the injectable administration solution of the present invention prepared by mixing the injectable preparation with an infusion solution or diluent and a pH adjuster at the time of use is stable even at a high concentration. Can exhibit excellent antibacterial action against MRSA without causing hematologic abnormalities at times.
- the WAP-8294A injection preparation solution of the present invention contains a high concentration of WAP-8294A.
- the injectable preparation of the present invention dissolves the antibiotic WAP-8294A having the above structural formula (1).
- Antibiotic WAP-8294A as an active ingredient has a structure represented by the above formula (1) and is hydrochloride
- antibiotics belonging to the genus Lyspactor such as Lysobacter sp. WAP-8294 strain (FERM BP — 4990) can be used.
- -Cultivate 8294A producing bacteria There is a method in which the antibiotic WAP-8294A is isolated and collected from the culture, and further separated and purified to obtain the antibiotic WAP-8294A.
- WAP-8294A is isolated as the hydrochloride salt
- the 2-hydroxypropyl- ⁇ -cyclodextrin contained in the injectable pharmaceutical solution of the present invention is preferably used in the range of 1% to 50%, particularly preferably 5% to 20%.
- the use concentration of 13-cyclodextrin is preferably 0.5% to 2.5%, particularly preferably 1% to 2%.
- WAP-8294AP is 5mgZmL to 20mgZmL.
- the injectable administration liquid of the present invention can be prepared by mixing the injectable preparation liquid with an infusion solution or a diluting solution at the time of use, and adding a rhodium regulator. It is preferable to adjust ⁇ of this administration solution to 6-8.
- the amount of infusion or dilution solution to be added is appropriate considering the WAP-8294- concentration in the injectable preparation, the amount appropriate for the administration solution, the dose of WAP-8294 ⁇ , etc.
- the dosing solution can be prepared to a considerably high concentration of about 7.5 mgZmL, but is preferably prepared at a concentration of 0.1 mgZmL to 5 mgZmL, particularly preferably 0.1 mgZmL to 3 mgZmL.
- precipitation occurs and stability is poor even at about 0.1 mgZmL.
- hematologic abnormalities may occur after administration.
- the infusion or diluent is not particularly limited as long as it is generally used, and dextrose is preferable from the viewpoint of power stability.
- dextrose is preferable from the viewpoint of power stability.
- the administration liquid of the present invention may further contain additives commonly used in preparations such as preservatives.
- the administration solution of the present invention can be administered as an infusion for injection, and is useful as a therapeutic agent for bacterial infections, particularly methicillin-resistant Staphylococcus aureus infections.
- the dosage of the preparation of the present invention varies depending on the target disease, administration route, frequency of administration, patient's symptom, etc.
- the amount of antibiotic WAP-8294A is, for example, per day for adults
- WAP-8294A API 1 Og prepared with distilled water for injection 16% 2-hydroxy Dissolved in 200 ml of propyl- ⁇ -cyclodextrin solution to obtain a WAP-8294A formulation solution for injection without adjusting the pH. The resulting formulation solution was stable for 6 months at room temperature.
- WAP-8294A API Og prepared with distilled water for injection 5% 2-hydroxy
- WAP-8294A API Og prepared with distilled water for injection 2% ⁇ -cyclode
- WAP-8294A formulation for injection that dissolves in 100 ml of cistrin solution and adjusts pH
- the prepared administration solution had a pH of 6.9 and an osmotic pressure of 230 mOsm / kg. In addition, the obtained applied solution was stable at room temperature for 24 hours.
- WAP-8294A of the present invention prepared by the method as shown in Example 4 for injection
- mice were repeatedly administered for 4 days for 3 doses of mg / kg / day, lOmgZkgZ day, and 2 mgZkgZ day, and the observed toxicity was compared. These doses should be WAP-8294A concentrations These are 7.5 mg / mL, 1.5 mg / mL, and 0.3 mgZmL, respectively.
- the WAP-8294A injection administration solution of the present invention showed significant toxicological improvements such as an increase in the lethal dose and reduction in hematological toxicity.
- the WAP-8294A administration solution of the present invention has excellent efficacy against MRSA-infected mice
- a ready-to-use injectable preparation is provided.
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/306,663 US7968588B2 (en) | 2006-06-29 | 2007-06-28 | Injectable formulation of antibiotic and solution for intravenous administration thereof |
DK07767796.1T DK2047857T3 (da) | 2006-06-29 | 2007-06-28 | Middel til injektionsformål omfattende antibiotika og opløsning til injektion omfattende midlet |
AU2007266063A AU2007266063B2 (en) | 2006-06-29 | 2007-06-28 | Injectable formulation of antibiotic and solution for intravenous administration thereof |
BRPI0713080-5A BRPI0713080A2 (pt) | 2006-06-29 | 2007-06-28 | formulação injetável de antibiótico e solução para administração intravenosa da mesma |
JP2008522624A JP5272126B2 (ja) | 2006-06-29 | 2007-06-28 | 抗生物質の注射剤及びその投与液 |
MX2009000155A MX2009000155A (es) | 2006-06-29 | 2007-06-28 | Formulacion inyectable de antibiotico y solucion para su administracion intravenosa. |
ES07767796T ES2378279T3 (es) | 2006-06-29 | 2007-06-28 | Agente destinado a ser utilizado para una inyección que comprende antibiótico, y solución para inyección que comprende el agente |
KR1020097001274A KR101286038B1 (ko) | 2006-06-29 | 2007-06-28 | 항생 물질의 주사제 및 그 투여액 |
EP07767796A EP2047857B1 (en) | 2006-06-29 | 2007-06-28 | Agent for injection purposes comprising antibiotic, and solution for injection comprising the agent |
CN2007800322662A CN101578103B (zh) | 2006-06-29 | 2007-06-28 | 抗生素的注射剂及其给予液 |
PL07767796T PL2047857T3 (pl) | 2006-06-29 | 2007-06-28 | Środek przeznaczony do wstrzykiwania zawierający antybiotyk i roztwór do wstrzykiwania zawierający środek |
CA2656604A CA2656604C (en) | 2006-06-29 | 2007-06-28 | Injectable formulation of antibiotic and solution for intravenous administration thereof |
AT07767796T ATE539761T1 (de) | 2006-06-29 | 2007-06-28 | Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006179778 | 2006-06-29 | ||
JP2006-179778 | 2006-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008001849A1 true WO2008001849A1 (fr) | 2008-01-03 |
Family
ID=38845613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/063003 WO2008001849A1 (fr) | 2006-06-29 | 2007-06-28 | Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent |
Country Status (17)
Country | Link |
---|---|
US (1) | US7968588B2 (ja) |
EP (1) | EP2047857B1 (ja) |
JP (1) | JP5272126B2 (ja) |
KR (1) | KR101286038B1 (ja) |
CN (1) | CN101578103B (ja) |
AT (1) | ATE539761T1 (ja) |
AU (1) | AU2007266063B2 (ja) |
BR (1) | BRPI0713080A2 (ja) |
CA (1) | CA2656604C (ja) |
DK (1) | DK2047857T3 (ja) |
ES (1) | ES2378279T3 (ja) |
MX (1) | MX2009000155A (ja) |
PL (1) | PL2047857T3 (ja) |
PT (1) | PT2047857E (ja) |
RU (1) | RU2462261C2 (ja) |
SI (1) | SI2047857T1 (ja) |
WO (1) | WO2008001849A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012005481A (ja) * | 2010-05-25 | 2012-01-12 | Genome Soyaku Kenkyusho:Kk | 抗生物質含有画分、その抗生物質及びその抗生物質の製造方法 |
JP2012006917A (ja) * | 2010-05-25 | 2012-01-12 | Genome Soyaku Kenkyusho:Kk | 新規環状ペプチド化合物とその製造方法及び感染症治療薬 |
JP2021504369A (ja) * | 2017-11-30 | 2021-02-15 | サイトジェル ファーマ リミテッド ライアビリティ カンパニー | 新規の鎮痛薬製剤処方及びその使用 |
US11603385B2 (en) | 2017-06-24 | 2023-03-14 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101931880A (zh) | 2009-06-19 | 2010-12-29 | 中兴通讯股份有限公司 | 一种多媒体广播组播业务动态复用的资源分配方法 |
CA3046458A1 (en) * | 2016-12-14 | 2018-06-21 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
KR102434276B1 (ko) | 2017-12-08 | 2022-08-18 | 엘지디스플레이 주식회사 | 표시장치 |
CN112236163A (zh) * | 2018-06-13 | 2021-01-15 | 京都生物制药株式会社 | 使用协同量的硼酸增强缩酚酸肽抗生素的抗菌作用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08273A (ja) * | 1994-02-18 | 1996-01-09 | Wakamoto Pharmaceut Co Ltd | 抗生物質wap−8294a、その製造法及び抗菌剤 |
JPH10139663A (ja) * | 1996-11-14 | 1998-05-26 | Yasutake Hichi | 神経毒軽減麻酔剤 |
JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−2製剤 |
JP2003183154A (ja) * | 2001-12-20 | 2003-07-03 | Mitsubishi Pharma Corp | ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法 |
WO2003094889A1 (fr) * | 2002-05-13 | 2003-11-20 | Daiichi Pharmaceutical Co., Ltd. | Produit de lyophilisation |
US20050239692A1 (en) | 2002-06-24 | 2005-10-27 | Hiltrud Lindenblatt | Aqueous preparation containing oligopeptides and etherified cyclodextrin |
JP2006143699A (ja) * | 2004-11-24 | 2006-06-08 | Yung Shin Pharmaceutical Industry Co Ltd | パクリタキセル水性注射液及びその調製方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100225601B1 (ko) * | 1995-02-02 | 1999-10-15 | 오쿠다 기요아키 | 항생물질 wap-8294a와 이의 제조방법 및 항균조성물 |
KR19980033113A (ko) | 1996-10-25 | 1998-07-25 | 야스다케 히지 | 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법 |
US6869927B1 (en) * | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
EP1171150A2 (en) * | 1999-04-15 | 2002-01-16 | Eli Lilly And Company | Pseudomycin antifungal compositions and methods for their use |
BR0308475A (pt) * | 2002-03-20 | 2005-01-11 | Pharmacia Corp | Formulação de eplerenona estável na armazenagem |
AUPS188302A0 (en) * | 2002-04-22 | 2002-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
-
2007
- 2007-06-28 DK DK07767796.1T patent/DK2047857T3/da active
- 2007-06-28 CN CN2007800322662A patent/CN101578103B/zh not_active Expired - Fee Related
- 2007-06-28 JP JP2008522624A patent/JP5272126B2/ja not_active Expired - Fee Related
- 2007-06-28 SI SI200730847T patent/SI2047857T1/sl unknown
- 2007-06-28 BR BRPI0713080-5A patent/BRPI0713080A2/pt not_active Application Discontinuation
- 2007-06-28 ES ES07767796T patent/ES2378279T3/es active Active
- 2007-06-28 AT AT07767796T patent/ATE539761T1/de active
- 2007-06-28 WO PCT/JP2007/063003 patent/WO2008001849A1/ja active Search and Examination
- 2007-06-28 KR KR1020097001274A patent/KR101286038B1/ko not_active IP Right Cessation
- 2007-06-28 RU RU2009102803/15A patent/RU2462261C2/ru not_active IP Right Cessation
- 2007-06-28 PL PL07767796T patent/PL2047857T3/pl unknown
- 2007-06-28 CA CA2656604A patent/CA2656604C/en not_active Expired - Fee Related
- 2007-06-28 US US12/306,663 patent/US7968588B2/en not_active Expired - Fee Related
- 2007-06-28 AU AU2007266063A patent/AU2007266063B2/en not_active Ceased
- 2007-06-28 MX MX2009000155A patent/MX2009000155A/es active IP Right Grant
- 2007-06-28 EP EP07767796A patent/EP2047857B1/en not_active Not-in-force
- 2007-06-28 PT PT07767796T patent/PT2047857E/pt unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08273A (ja) * | 1994-02-18 | 1996-01-09 | Wakamoto Pharmaceut Co Ltd | 抗生物質wap−8294a、その製造法及び抗菌剤 |
US5648455A (en) | 1994-02-18 | 1997-07-15 | Wakamoto Pharmaceutical Co., Ltd. | Antibiotic WAP-8294A, method for preparing the same and antibacterial composition |
JP3339235B2 (ja) | 1994-02-18 | 2002-10-28 | 日本メディカルリサーチ株式会社 | 抗生物質wap−8294a、その製造法及び抗菌剤 |
JPH10139663A (ja) * | 1996-11-14 | 1998-05-26 | Yasutake Hichi | 神経毒軽減麻酔剤 |
JP2003500456A (ja) * | 1999-06-02 | 2003-01-07 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−2製剤 |
JP2003183154A (ja) * | 2001-12-20 | 2003-07-03 | Mitsubishi Pharma Corp | ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法 |
WO2003094889A1 (fr) * | 2002-05-13 | 2003-11-20 | Daiichi Pharmaceutical Co., Ltd. | Produit de lyophilisation |
US20050239692A1 (en) | 2002-06-24 | 2005-10-27 | Hiltrud Lindenblatt | Aqueous preparation containing oligopeptides and etherified cyclodextrin |
JP2005534671A (ja) * | 2002-06-24 | 2005-11-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | オリゴペプチドとエーテル化シクロデキストリンを含む液体製剤 |
JP2006143699A (ja) * | 2004-11-24 | 2006-06-08 | Yung Shin Pharmaceutical Industry Co Ltd | パクリタキセル水性注射液及びその調製方法 |
Non-Patent Citations (1)
Title |
---|
HARADA K.-I. ET AL.: "Separation of WAP-8294A components, a novel anti-methicillin-resistant staphylococcus aureus antibiotic, using high-speed counter-current chromatography", J. CHROMATOGR., vol. 932, no. 1-2, 2001, pages 75 - 81, XP004308399 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012005481A (ja) * | 2010-05-25 | 2012-01-12 | Genome Soyaku Kenkyusho:Kk | 抗生物質含有画分、その抗生物質及びその抗生物質の製造方法 |
JP2012006917A (ja) * | 2010-05-25 | 2012-01-12 | Genome Soyaku Kenkyusho:Kk | 新規環状ペプチド化合物とその製造方法及び感染症治療薬 |
US11603385B2 (en) | 2017-06-24 | 2023-03-14 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
JP2021504369A (ja) * | 2017-11-30 | 2021-02-15 | サイトジェル ファーマ リミテッド ライアビリティ カンパニー | 新規の鎮痛薬製剤処方及びその使用 |
JP7226830B2 (ja) | 2017-11-30 | 2023-02-21 | サイトジェル ファーマ リミテッド ライアビリティ カンパニー | 新規の鎮痛薬製剤処方及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2007266063A1 (en) | 2008-01-03 |
ATE539761T1 (de) | 2012-01-15 |
RU2009102803A (ru) | 2010-08-10 |
EP2047857A1 (en) | 2009-04-15 |
PT2047857E (pt) | 2012-03-15 |
BRPI0713080A2 (pt) | 2012-10-09 |
CN101578103A (zh) | 2009-11-11 |
AU2007266063B2 (en) | 2011-09-08 |
EP2047857A4 (en) | 2010-05-26 |
CA2656604A1 (en) | 2008-01-03 |
JP5272126B2 (ja) | 2013-08-28 |
ES2378279T3 (es) | 2012-04-10 |
CA2656604C (en) | 2014-01-07 |
RU2462261C2 (ru) | 2012-09-27 |
JPWO2008001849A1 (ja) | 2009-11-26 |
SI2047857T1 (sl) | 2012-03-30 |
KR101286038B1 (ko) | 2013-07-19 |
US7968588B2 (en) | 2011-06-28 |
US20090258920A1 (en) | 2009-10-15 |
MX2009000155A (es) | 2009-03-25 |
KR20090030317A (ko) | 2009-03-24 |
CN101578103B (zh) | 2013-09-25 |
EP2047857B1 (en) | 2012-01-04 |
DK2047857T3 (da) | 2012-02-27 |
PL2047857T3 (pl) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008001849A1 (fr) | Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent | |
CN102448496B (zh) | 含碘和类固醇的药物组合物及其用于治疗鼻炎疾病的用途 | |
AU2018322769B2 (en) | Daptomycin formulations | |
ES2393675T3 (es) | Composición conservante para uso oftálmico | |
CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
JP2019515023A (ja) | 細菌感染症を治療するためのシステム及び方法 | |
CN110869023B (zh) | 原位凝胶形成药物组合物及其在鼻窦疾病中的应用 | |
CA3157999A1 (en) | Injectable compositions of ursodeoxycholic acid | |
CN114306218B (zh) | 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物 | |
CN103070881A (zh) | 一种阴道抑菌、杀病毒组合物及其应用 | |
WO2017038872A1 (ja) | 抗真菌活性を有する組成物 | |
JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
WO2003070231A1 (fr) | Compositions antibacteriennes | |
KR20210031466A (ko) | 상승 작용량의 붕산을 이용한 뎁시펩타이드 항생제의 항균 작용 증진 | |
US11351192B2 (en) | De-colonization drug, preparation method therefor, and application thereof | |
US20220071902A1 (en) | Solution and method for reducing the virulence of viruses, bacteria, yeasts, or fungus | |
RU2487702C2 (ru) | Лекарственное средство для лечения туберкулеза | |
JP4875813B2 (ja) | 抗真菌組成物 | |
Muller et al. | Daptomycin | |
US20230357329A1 (en) | Combined use of nanobody, cyclodextrin and quercetin for protection from enveloped viruses | |
RU2466722C2 (ru) | Противотуберкулезное средство | |
JP2000229863A (ja) | 咽頭疾患用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780032266.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07767796 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008522624 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2656604 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007266063 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/000155 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097001274 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007767796 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007266063 Country of ref document: AU Date of ref document: 20070628 Kind code of ref document: A Ref document number: 2009102803 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 532/CHENP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12306663 Country of ref document: US |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: PI0713080 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081229 |